Replies to post #2962 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

Thanks Smeagol.

I've read some of your posts. You sound like you have a lot of knowledge of the oncology space (which is good, in that it seems that your posts/predictions aren't dictated by your brokerage statement like many others).

Q3 or Q4 would be good for data. Taking in to account with what the FDA just did with T-DM1 and their shortened data (which showed great results), do you think that they would take the same route (the FDA) as they did with Immunogen (asking for full/longer data).

BTW, what do you think the chances that after a sustained positive duration, Ponatinib itself develops resistance, or the protein develops another mutation???